BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26681989)

  • 1. EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.
    Wang T; Gantier MP; Xiang D; Bean AG; Bruce M; Zhou SF; Khasraw M; Ward A; Wang L; Wei MQ; AlShamaileh H; Chen L; She X; Lin J; Kong L; Shigdar S; Duan W
    Theranostics; 2015; 5(12):1456-72. PubMed ID: 26681989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
    Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
    PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
    Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
    Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule.
    Shigdar S; Lin J; Yu Y; Pastuovic M; Wei M; Duan W
    Cancer Sci; 2011 May; 102(5):991-8. PubMed ID: 21281402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.
    Xiang D; Shigdar S; Bean AG; Bruce M; Yang W; Mathesh M; Wang T; Yin W; Tran PH; Al Shamaileh H; Barrero RA; Zhang PZ; Li Y; Kong L; Liu K; Zhou SF; Hou Y; He A; Duan W
    Theranostics; 2017; 7(17):4071-4086. PubMed ID: 29158811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells.
    Gilboa-Geffen A; Hamar P; Le MT; Wheeler LA; Trifonova R; Petrocca F; Wittrup A; Lieberman J
    Mol Cancer Ther; 2015 Oct; 14(10):2279-91. PubMed ID: 26264278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells.
    AlShamaileh H; Wang T; Xiang D; Yin W; Tran PH; Barrero RA; Zhang PZ; Li Y; Kong L; Liu K; Zhou SF; Hou Y; Shigdar S; Duan W
    Sci Rep; 2017 Jul; 7(1):5898. PubMed ID: 28724889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-walled carbon nanotubes functionalized with aptamer and piperazine-polyethylenimine derivative for targeted siRNA delivery into breast cancer cells.
    Mohammadi M; Salmasi Z; Hashemi M; Mosaffa F; Abnous K; Ramezani M
    Int J Pharm; 2015 May; 485(1-2):50-60. PubMed ID: 25712164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR, MRI and CT imaging.
    Roy K; Kanwar RK; Kanwar JR
    Biomaterials; 2015 Dec; 71():84-99. PubMed ID: 26318819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Cancer Cells Using LNA-Modified Aptamer-siRNA Chimeras.
    Subramanian N; Kanwar JR; Kanwar RK; Krishnakumar S
    Nucleic Acid Ther; 2015 Dec; 25(6):317-22. PubMed ID: 26334953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.
    Subramanian N; Raghunathan V; Kanwar JR; Kanwar RK; Elchuri SV; Khetan V; Krishnakumar S
    Mol Vis; 2012; 18():2783-95. PubMed ID: 23213278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
    Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
    Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
    Montazeri Aliabadi H; Landry B; Mahdipoor P; Uludağ H
    Mol Pharm; 2011 Oct; 8(5):1821-30. PubMed ID: 21838308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex.
    Subramanian N; Kanwar JR; Athalya PK; Janakiraman N; Khetan V; Kanwar RK; Eluchuri S; Krishnakumar S
    J Biomed Sci; 2015 Jan; 22():4. PubMed ID: 25576037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM-Antibody-Labeled Noncytotoxic Polymer Vesicles for Cancer Stem Cells-Targeted Delivery of Anticancer Drug and siRNA.
    Chen J; Liu Q; Xiao J; Du J
    Biomacromolecules; 2015 Jun; 16(6):1695-705. PubMed ID: 25988863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
    Alibolandi M; Ramezani M; Abnous K; Sadeghi F; Atyabi F; Asouri M; Ahmadi AA; Hadizadeh F
    J Control Release; 2015 Jul; 209():88-100. PubMed ID: 25912964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.
    Zheng J; Zhao S; Yu X; Huang S; Liu HY
    Theranostics; 2017; 7(5):1373-1388. PubMed ID: 28435472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model.
    Mashreghi M; Zamani P; Karimi M; Mehrabian A; Arabsalmani M; Zarqi J; Moosavian SA; Jaafari MR
    Biotechnol Prog; 2021 May; 37(3):e3116. PubMed ID: 33369269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
    Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
    Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.